Abstract | AIM: We investigated the effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in hyperlipidemic endstage renal disease patients on chronic hemodialysis (HD). METHODS: In 25 hyperlipidemic HD patients who received 10 mg of simvastatin for 6 months and another 25 controls, the extended lipid profile and serum hsIL-6, MCP-1, sICAM-1, sVCAM-1, and sE- selectin, plasma oxLDL, and serum sFas and sFasL levels were determined at baseline, 3 months and 6 months. In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry. RESULT:
Simvastatin treatment resulted in significant reductions in serum lipid levels at 3 months and beyond, compared to at baseline. Moreover, at 6 months, simvastatin caused a significant reduction in CRP (p < 0.001), which correlated to the decrease in total and LDL cholesterol levels, as well as a significant reduction in IL-6 (p=0.001), sICAM-1 (p < 0.001), sVCAM-1 (p < 0.001), oxLDL (p=0.001), sFas (p=0.02) and CD14 expression (p < 0.001), compared to baseline values. No significant changes in the controls were noticed during the study. CONCLUSION: In conclusion, in hyperlipidemic HD patients, simvastatin treatment resulted in a significant reduction in markers of endothelial dysfunction, inflammation, oxidative stress, endothelial cell apoptosis and peripheral blood monocyte stimulation. The reduction in CRP appears to be related to the lipid-lowering effects of simvastatin.
|
Authors | Dimitrios Kirmizis, Aikaterini Papagianni, Fani Dogrammatzi, Lemonia Skoura, Anna-Maria Belechri, Efstathios Alexopoulos, Georgios Efstratiadis, Dimitrios Memmos |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 17
Issue 12
Pg. 1256-65
(Dec 26 2010)
ISSN: 1880-3873 [Electronic] Japan |
PMID | 20885069
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers
- Hypolipidemic Agents
- Lipids
- C-Reactive Protein
- Simvastatin
|
Topics |
- Apoptosis
(drug effects)
- Biomarkers
(blood)
- C-Reactive Protein
(analysis)
- Case-Control Studies
- Endothelial Cells
(drug effects)
- Humans
- Hypolipidemic Agents
(pharmacology)
- Inflammation
(drug therapy)
- Kidney Failure, Chronic
(drug therapy, pathology, therapy)
- Lipids
(blood)
- Monocytes
(drug effects)
- Oxidative Stress
(drug effects)
- Renal Dialysis
- Simvastatin
(pharmacology)
|